Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CARMUSTINE vs CASIRIVIMAB\IMDEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CARMUSTINE vs CASIRIVIMAB\IMDEVIMAB: Safety Overview

Metric CARMUSTINE CASIRIVIMAB\IMDEVIMAB
Total FAERS Reports 3,376 4,248
Deaths Reported 781 137
Death Rate 23.1% 3.2%
Hospitalizations 873 1,351
Average Patient Age 52.0 yrs 54.3 yrs
% Female Patients 33.8% 55.4%
FDA Approval Date Approved Prior to Jan 1, 1982 N/A
Manufacturer Amneal Pharmaceuticals LLC N/A
Route INTRAVENOUS N/A
Marketing Status Prescription N/A